Navigation Links
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis

improved, unchanged and worsened by 64.3%, 21.4% and 14.3%, respectively. The EDSS for a 0.5 point sustained (no change over 3 months) effect was improved, unchanged and worsened by 42.9%, 42.9% and 14.2%, respectively. The EDSS for a 1.0 sustained effect was improved, unchanged and worsened by 28.6%, 57.1% and 14.3%, respectively.

Brian Loftus, M.D. of Bellaire Neurology, the Principal Investigator of these Tovaxin studies, commented, "This data, combined with prior data presented on myelin reactive T-cell frequencies and ARR reductions, laid the ground work for the placebo-controlled Tovaxin IIb clinical trial (TERMS). We have shown that myelin reactive T-cells can be identified and used to produce T-cell vaccine which effectively induces the depletion of an individual's autoreactive T-cells and results in positive clinical outcomes. I anticipate Tovaxin will usher in the age of personalized therapy for MS."

David McWilliams, president and chief executive officer of Opexa, said, "We are particularly encouraged by the data from this extension trial which indicates that subjects previously treated with T-cell vaccine can be safely and effectively retreated with Tovaxin. This outcome is important to our planned extension trial for subjects currently enrolled in our TERMS trial following the one year core study time period." In addition, the effectiveness data in RRMS subjects across the two Phase I/II trials indicate strongly positive outcomes in both ARR and EDSS improvements following Tovaxin therapy."

About TERMS

The Tovaxin Phase IIb clinical study will include 150 patients in a multicenter, randomized, double blind, placebo-controlled trial designed primarily to evaluate the efficacy, safety and tolerability of the Tovaxin T-cell vaccination with clinically isolated syndrome (CIS) and relapsing-remitting MS (RR-MS) patients. A total of 100 patients will receive Tovaxin, while 50 will receive placebo. The study is designed as a two-ar
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:10/30/2014)... 2014 The global market for human ... introduction of new vaccines. These new products and ... Market. The Kalorama information report examines the global ... developmental vaccines for diseases that are already vaccine-preventable. ... entire communities from diseases spread by person-to-person transmission. ...
(Date:10/27/2014)... , Oct. 27, 2014  RenovoRx, a leading developer ... and delivery of fluids to selected sites in the ... Directors has appointed Shaun Bagai as Chief ... RenovoRx Board of Directors. Bagai brings more than 15 ... Bagai joined RenovoRx in June 2014 and in ...
(Date:10/27/2014)... , Oct. 27, 2014  In the last few weeks, Ebola ... Africa to a worldwide crisis when a traveler ... virus and died, and two nurses were infected. While ... happen, the use of modern technology, such as electronic health records ... This week, InformationWeek Healthcare Editor Alison Diana ...
Breaking Medicine Technology:Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 2Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 3RenovoRx Board Names Shaun R. Bagai as CEO 2EHRs in the Age of Ebola: Discuss on InformationWeek 2EHRs in the Age of Ebola: Discuss on InformationWeek 3
... SAN DIEGO, Jan. 17, 2012  Janssen Research & ... San Diego, a 30,000-square-foot life science innovation center, ... Center.  The innovation center provides a capital efficient, ... technologies and research platforms to advance medical care. ...
... Jan. 17, 2012   ULURU Inc. (NYSE AMEX: ... Melmed Holdings AG for the marketing of Altrazeal® ... Africa has been finalized. Under the terms of ... marketing of Altrazeal® to Melmed Holdings AG, who are establishing ...
Cached Medicine Technology:Janssen Research & Development, LLC Opens JANSSEN LABS at San Diego 2Janssen Research & Development, LLC Opens JANSSEN LABS at San Diego 3Janssen Research & Development, LLC Opens JANSSEN LABS at San Diego 4ULURU Inc. Completes Altrazeal® License Agreement for Europe 2ULURU Inc. Completes Altrazeal® License Agreement for Europe 3
(Date:10/30/2014)... have to be at least 2 years old to ... no official U.S. guidance exists other than the general ... breastfeed for at least the first six months. , ... That,s the question that motivated researchers at the University ... study the eating patterns of American infants at 6 ...
(Date:10/30/2014)... 2014 Nutrition Leaders, a popular online ... aids, and more, is currently hosting a sweepstakes on ... underway, is open to U.S. residents age 18 and ... 2014. One lucky winner will then be selected at ... gift card to NutritionLeaders.com. , Nutrition Leaders’ managing director ...
(Date:10/30/2014)... Burlington, NC (PRWEB) October 30, 2014 ... life, commercial, and health insurance plans for North Carolina ... its satellite office in Burlington’s Holly Hill Mall. The ... 15, with agents already helping customers through all facets ... policy purchase. , Allred Insurance spokesman Scott Allred couldn’t ...
(Date:10/30/2014)... PreDiabetes Centers , the pioneer in prediabetes ... a supply of sugardown®, a chewable dietary supplement that ... spikes. Learning how to control blood sugar levels and ... diabetes prevention plan. , Shoppers who spend $50 or ... sugardown. The offer expires November 30. , Full-size ...
(Date:10/30/2014)... Steven Reinberg HealthDay Reporter , ... to men with prostate cancer who also have certain heart ... cause, a new study suggests. , , The therapy in question ... cancer to reduce levels of male hormones to prevent the ... the current research, this hormone therapy was linked to triple ...
Breaking Medicine News(10 mins):Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 2Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 3Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Allred Insurance Satellite Office Grand Opening 2Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3
... social science research organization NORC at the University of Chicago contradicts ... above age 80. It also explains why there ... and above than the Census Bureau predicted there would be as ... a new way of accurately measuring mortality of Americans who are ...
... at NYU Langone Medical Center will present their latest ... tendon, bone and joint at the annual meeting of ... in San Francisco, California. "The introduction ... in clinical care, allows our researchers to identify the ...
... a way to study how our brains assess the behavior ... Their study, described in a paper in the ... to use a computational approach to tease out differing patterns of ... compete against each other in a game, they try to make ...
... At a time when there is tremendous concern about ... and the costs of technology, the Canadian Institutes of ... to improve end of life decision making amongst seriously ... receiving funding for this initiative. , "Canada,s aging population ...
... Institutet, has received a grant of 1.6 million Euro ... the fundamental causes of diabetes. The grant will make ... the release of insulin is regulated in living organisms ... more effective drugs against diabetes. , Diabetes is an ...
... a few years, a new generation of easy-to-use blood-thinning drugs ... are at risk for stroke, according to a journal article ... new drugs do not require patients to come in to ... Nor do the drugs require extensive dietary restrictions. , First ...
Cached Medicine News:Health News:Odds of living a very long life lower than formerly predicted 2Health News:Odds of living a very long life lower than formerly predicted 3Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 2Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 3Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 4Health News:It's not solitaire: Brain activity differs when one plays against others 2Health News:CIHR invests in Queen's-led study on end-of-life decision making 2Health News:Donation opens new opportunities for more effective diabetes treatment 2Health News:Easy-to-use blood thinners likely to replace Coumadin 2
... is enzyme immunoassay kit for the ... concentration in serum. Enzyme immunoassay (EIA) ... many protein hormones in body fluids ... rapid and specific assay. This enzyme ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... method for the semi-quantitative determination of ... human serum. The results of the ... an aid in the diagnosis of ... with elevated anti-neutrophil cytoplasmic antibodies (P-ANCA) ...
... The determination of Ang ... in monitoring the pharmacological effect ... variety of angiotensin converting enzyme ... II receptor antagonists as well ...
Medicine Products: